Clear Search

Showing 1 result for “Kastbom A”.

March 2022

Efectividad de baricitinib y tofacitinib frente a bDMARDs en AR: resultados de un estudio de cohorte utilizando los datos del registro nacional sueco

Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac068

Data from the Swedish Rheumatology Quality Register and Swedish Registries, show a higher treatment retention and overall equivalent or better treatment response on baricitinib, compared with bDMARDs or tofacitinib, but no statistically significant differences between tofacitinib and bDMARDs.In this largest population-based study to date, comparing RA patients initiating baricitinib, tofacitinib or bDMARDs, Barbulescu, et al. help to fill some of the current knowledge gaps surrounding the effica...

mas…